Leslie Nangle Greene
Vice President - Research aTyr Pharma Inc.
Dr. Leslie Nangle leads research efforts at aTyr Pharma, where since she has helped build a discovery platform focused on extracellular tRNA synthetases and immune modulation. Holding a PhD from The Scripps Research Institute under the mentorship of Dr. Paul Schimmel, she has authored over 75 publications and holds a robust IP portfolio. Her leadership has driven the development of aTyr’s lead program, ATYR1923, a therapeutic targeting Neuropilin-2 in inflammatory lung diseases.
Seminars
Thursday 3rd December 2026
Exploiting Extracellular Matrix–Myofibroblast Interactions to Selectively Eliminate Fibrosis-Driving Cells
3:00 pm
- Disrupting ECM-driven myofibroblast adhesion to promote selective myofibroblast apoptosis
- Understanding how diseased ECM influences early fibrotic signalling & creates new therapeutic intervention points
- Demonstrating activity across preclinical lung & kidney fibrosis models while assessing organ-specific ECM biology
- Applying artificial intelligence (AI)-guided indication selection to identify where an early ECM-focused programme could deliver the greatest impact
